Clinical Trial Detail

NCT ID NCT03633331
Title Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Alliance for Clinical Trials in Oncology
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Letrozole + Palbociclib

Age Groups: senior

Additional content available in CKB BOOST